Peroxisome proliferator–activated receptor α (PPAR α) is a nuclear receptor of clinical
interest as a drug target in various metabolic disorders. PPAR α also exhibits marked anti …

The human body cannot store zinc reserves, so a deficiency can arise relatively quickly, eg,
through an improper diet. Severe zinc deficiency is rare, but mild deficiencies are common …

Obesity and hyperlipidemia are the most prevalent independent risk factors of chronic
kidney disease (CKD), suggesting that lipid accumulation in the renal parenchyma is …

Agonists of the nuclear receptor PPARγ are therapeutically used to combat hyperglycaemia
associated with the metabolic syndrome and type 2 diabetes. In spite of being effective in …

Phthalates are pervasive compounds, and due to the ubiquitous usage of phthalates,
humans or even children are widely exposed to them. Since phthalates are not chemically …

Inflammation clearly occurs in pathologically vulnerable regions of the Alzheimer's disease
(AD) brain, and it does so with the full complexity of local peripheral inflammatory responses …

B. DNA binding properties C. PPAR ligand-binding properties D. Alternative pathways for
PPAR activation E. PPAR-mediated transactivation properties III. Physiological Aspects A …

The peroxisome proliferator-activated receptor-γ (PPAR-γ) is a member of the nuclear
receptor superfamily of ligand-dependent transcription factors that is predominantly …

The peroxisome proliferator-activated receptor-γ (PPAR-γ) is a member of the nuclear
receptor family of transcription factors, a large and diverse group of proteins that mediate …

The lack of therapy and the failure of existing therapy has been a challenge for clinicians in
treating various cancers. Doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel are the first-line …